Clinical Trials Logo

Filter by:
NCT ID: NCT01631825 Completed - Parkinson's Disease Clinical Trials

A Long-Term Extension Trial From of SPM 962 in Advanced Parkinson's Disease Patients

Start date: October 2009
Phase: Phase 3
Study type: Interventional

- To investigate the safety of once-daily repeated transdermal administration of SPM 962 within a dose range of 4.5 to 36.0 mg/day (54-week treatment period) in Parkinson's disease (PD) patients treated concomitantly with L-dopa in a multi-center, open-label uncontrolled study. - To investigate efficacy of SPM 962 in an exploratory manner.

NCT ID: NCT01631812 Completed - Parkinson's Disease Clinical Trials

A Long-Term Extension Trial From Late Phase II of SPM 962 in Advanced Parkinson's Disease Patients

Start date: December 2006
Phase: Phase 2
Study type: Interventional

The primary objective of this study is to investigate safety of SPM 962 in advanced PD patients in a multi-center, open-label, non-controlled study following once-daily multiple transdermal doses of SPM962 within a range of 4.5 to 36.0 mg (maximum treatment period: 54 weeks). Efficacy is also to be exploratory investigated.

NCT ID: NCT01630746 Completed - Erosive Esophagitis Clinical Trials

A Randomized, Double-Blind, Multicenter Study to Evaluate the Acid-inhibitory and Dose-response Efficacy of TAK-438 (20 mg, 40 mg) in Patients With Proton Pump Inhibitor (PPI) - Resistant Erosive Esophagitis

Start date: July 2012
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the acid-inhibitory and dose-response efficacy of TAK-438 (20 mg, 40 mg) in patients with PPI-resistant erosive esophagitis.

NCT ID: NCT01630135 Completed - Rhinitis Clinical Trials

Study FFR116364, a Placebo-controlled Study of GW685698X in Paediatric Subjects With Perennial Allergic Rhinitis

Start date: June 2012
Phase: Phase 3
Study type: Interventional

Efficacy and safety of GW685698X (55 µg/day, q.d.) nasal spray over a period of 2 weeks in Japanese paediatric subjects ages 6 to < 15 years with perennial allergic rhinitis will be evaluated compared with placebo.

NCT ID: NCT01629888 Completed - Healthy Clinical Trials

A Clinical Study for Evaluating the Safety of Excessive Consumption of a Plant Sterol-enriched Yoghurt Drink

Start date: February 2010
Phase: N/A
Study type: Interventional

The purpose of this study is to investigate the safety of consumption of three times the standard dose of a yoghurt drink enriched with 1600 mg of plant sterols.

NCT ID: NCT01629420 Completed - Endometriosis Clinical Trials

A Phase II Randomized Open Label Study of KLH-2109 in Patients With Endometriosis

Start date: n/a
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the efficacy and safety of KLH-2109 in patients with endometriosis.

NCT ID: NCT01628965 Completed - Parkinson's Disease Clinical Trials

A Long-Term Extension Trial From Phase II/III of SPM 962 in Early Parkinson's Disease Patients

Start date: January 2008
Phase: Phase 2/Phase 3
Study type: Interventional

Safety of SPM 962 in a once-daily repeated long-term treatment in Parkinson's disease patients who are not concomitantly treated with L-dopa will be investigated with a doses.

NCT ID: NCT01628926 Completed - Parkinson's Disease Clinical Trials

A Placebo- and Ropinirole-Controlled Study for SPM 962 in Advanced Parkinson's Disease Patients

Start date: June 2009
Phase: Phase 3
Study type: Interventional

- To demonstrate the non-inferiority of SPM 962 to ropinirole in terms of efficacy in order to confirm clinical value of SPM 962. - To demonstrate the superiority of SPM 962 to placebo in terms of efficacy. - To investigate the tolerability and safety of SPM 962 up to 36.0 mg/day.

NCT ID: NCT01628848 Completed - Parkinson's Disease Clinical Trials

A Dose-finding Study for SPM 962 in Advanced Parkinson's Disease Patients

Start date: August 2006
Phase: Phase 2
Study type: Interventional

The primary objective of this study is to investigate efficacy and safety of SPM 962 in advanced Parkinson's Disease (PD) patients in a multi-center, placebo-controlled study following once-daily multiple transdermal doses of SPM 962 within a range of 4.5 to 36.0 mg (12 weeks of dose titration/maintenance period). Recommended maintenance dose range is also to be investigated with distribution of the maintenance dose and accumulated response rate of efficacy.

NCT ID: NCT01626885 Completed - Schizophrenia Clinical Trials

A Long-Term Study of MP-214 in Patients With Receiving Multiple Drugs Schizophrenia

Start date: May 2012
Phase: Phase 2/Phase 3
Study type: Interventional

The objective of this study is to evaluate the long-term safety, tolerability, and efficacy of MP-214 in patients with receiving multiple drugs schizophrenia.